Multivariate analysis identifies specific diabetes drugs that modify sepsis risk in type 2 diabetes patients | Research

The takeaway

Multivariate analysis in T2DM patients identifies differential sepsis risk modification by antidiabetic drug classes, with GLP-1RAs and SGLT2i potentially reducing sepsis susceptibility through anti-inflammatory and immune-modulating mechanisms.

Drug choice affects sepsis risk
Some diabetes drugs (GLP-1RAs, SGLT2i) may reduce sepsis susceptibility through anti-inflammatory mechanisms—adding infection prevention to drug selection criteria

What the researchers found

Multivariate analysis: different antidiabetic drugs have differential sepsis risk effects. GLP-1RAs + SGLT2i: potential sepsis risk reduction via anti-inflammatory/immune pathways. T2DM: increased sepsis risk from immune dysfunction/inflammation.

Why it matters

Sepsis kills millions of diabetics annually. Knowing which diabetes drugs reduce sepsis risk could guide drug selection for high-risk patients—adding infection prevention to metabolic management.

How the study worked

Multivariate analysis of antidiabetic medication use and sepsis risk in T2DM patients.

What this study cannot tell us

Multivariate analysis from observational data. Confounding by indication likely. Cannot establish causation. Specific effect sizes not in preview.

How to read the evidence

Multivariate observational analysis. Hypothesis-generating.

When this study was published

Published in 2025.

The bigger picture

Drug selection in T2DM could optimize both metabolic control and infection prevention. GLP-1 drugs' anti-inflammatory effects may provide dual benefit: better glucose AND fewer infections.

Questions still open

Should sepsis risk guide diabetes drug selection in high-risk patients?
Do GLP-1 drugs reduce sepsis through direct immune effects or better glucose control?
Would prospective trials confirm the sepsis protection?

Common questions

Can diabetes drugs prevent infections?

This study suggests some can. GLP-1 drugs and SGLT2 inhibitors appear to reduce sepsis risk in diabetic patients through their anti-inflammatory properties—not just their blood sugar effects. This adds infection prevention to the reasons for choosing these newer drug classes.

Why are diabetics more prone to sepsis?

Diabetes impairs immune function and creates chronic inflammation, making patients more susceptible to severe infections. Understanding which diabetes medications can improve immune function while controlling blood sugar is important for comprehensive diabetic care.

Read the original research

Effect of Anti-Diabetic Medication Use on Sepsis Risk in Type 2 Diabetes Mellitus: A Multivariate Analysis.

Geriatrics (Basel, Switzerland), 10(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Ulambayar, Battamir; Ghanem, Amr Sayed; Nagy, Attila Csaba. (2025). Effect of Anti-Diabetic Medication Use on Sepsis Risk in Type 2 Diabetes Mellitus: A Multivariate Analysis.. Geriatrics (Basel, Switzerland), 10(4). https://doi.org/10.3390/geriatrics10040108